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Abstract 
Respiratory syncytial virus (RSV) is a major respiratory pathogen of young infants 
and the elderly and is associated with upper and lower respiratory disease. Vaccine 
development for RSV has been hindered by poor immunogenicity in target populations, 
genetic and physical instabilities, and a legacy of vaccine-enhanced disease. The fusion 
and attachment proteins of RSV, F and G, have been seen to be responsible for inducing 
the majority of neutralizing antibodies. However, little remains known about how 
differences in RSV F and G affect virus replication and stability. In this thesis, we 
proposed to examine the replication and thermal stability of a panel of recombinant RSV 
strains which express the F and G proteins of laboratory and clinical isolates. To evaluate 
thermal stability, the RSV panel was incubated at 4C, 32C, and 37C before 
determining reductions in infectious titer. In addition, since vaccine stocks are often 
subjected to repetitive cycles of freezing and thawing during transport and storage, we 
also evaluated stability following multiple cycles of freezing and thawing. Although the 
majority of strains in our panel were very unstable, one strain was shown to be 
significantly more stable than others at each temperature as well as at each freeze-thaw 
interval. Additionally, results showed no correlation between thermal stability and growth 
kinetics under normal conditions. We hope these results will provide insight into strain-
specific differences among RSV isolates as well as provide guidance for particular RSV 
strains or F and G isolates to use in vaccine preparation.        
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Introduction 
 
Viruses and Virology 
 Viruses are microscopic, nonliving parasites that are generally much smaller than 
bacterial cells. Viruses are not cells and do not infect like bacteria do, but they rather 
infect host cells by hijacking the machinery of the host cell to make several copies of 
themselves to infect other cells. A virus not associated with a host cell is known as a 
virion, and it is generally inactive. Viruses are considered nonliving because they cannot 
reproduce on their own but must use host cell machinery to create multiple copies of 
itself, and also, they cannot move on their own. Additionally, viruses lack any organelles 
to perform any kind of metabolic processes, a very common property of the definition of 
life. Some people, though, argue that viruses can be considered living because of their 
abilities to evolve to be able to infect a host more perfectly or to be able to infect more 
than one host, although they still need a host cell in order to evolve (30). Nearly every 
living thing on Earth can be infected by viruses, from bacteria to plants to humans, which 
is the area of virology most focused on by researchers. However, the first virus ever to be 
defined as such was one that infected a plant. 
Viruses were first discovered at the end of the 19th century when the tobacco 
mosaic disease was first examined. At the time, bacterial infections were thought to be 
the only cause of disease for both plants and animals. It was quite difficult for researchers 
at the time to determine the causative property of tobacco mosaic disease, as they could 
not find any incidence of bacteria. To give a comparison, viruses are generally about 40 
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times smaller than bacteria, so it was very difficult to determine what the substance 
causing disease was with the research methods available at the time (Figure 1). An 
experiment performed by Adolf Mayer in 1886 revealed that if leaves with the disease 
were crushed and mixed with healthy leaves, it resulted in symptoms of the disease in the 
healthy leaves. Mayer believed the pathogen was in the leafy excretions, but incorrectly 
tried to prove it to be bacterial which he was unable to see under a microscope. This 
experiment was repeated in 1892 by Dmitri Ivanovsky, who after crushing up the infected 
leaves, poured the liquid excretion through a filter that could capture bacteria, and found 
that the excretion was still infectious to healthy leaves. This suggested that the infectious 
agent was much smaller than bacteria, although Ivanovsky was still convinced the disease 
was bacterial. In 1898, Martinus Beijerinck interpreted Ivanovsky’s results differently, 
stating that the causative agent was not bacterial, but was a “filterable virus,” a now 
outdated term. Although viruses were first believed to exist at this time, a virus was not 
seen with the human eye until development of the electron microscope three decades 
later. Finally, in 1939, the tobacco mosaic virus was observed and Beijerinck’s 
conclusions were confirmed (31). 
The anatomy of a virus differs greatly from that of other infectious particles. A 
viral particle is simply the virus’s genome, whether it be single or double stranded DNA 
or RNA, in a protective coating that allows it to hijack host cell machinery. The outer 
coating of the virus, called a capsid, is a protein coat composed of proteins coded by the 
viral genome. Some viruses contain an envelope, which is an external membrane 
surrounding the envelope, which is a leftover part of the phospholipid membrane of the 
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Figure 1: Sizes of viruses relative to bacteria, human cells, and other biological 
substances 
  
Adapted from https://www.researchgate.net/figure/Relative-sizes-of-major-host-cells-and-their-
components-versus-those-of-bacteria-and_fig4_325937574 
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host cell it came from. Viruses that have an envelope leave the host cell via budding, 
rather than rupture of the host cell of other viruses. All viruses also contain surface 
proteins which facilitate interactions with the host cell and will eventually allow the virus 
to enter the host cell. These proteins are called fusion (F) proteins and glycoproteins (G 
proteins) (Figure 2). These surface proteins not only facilitate entry into the host cell but 
will also determine the range of hosts that a virus can infect, also called tropism (32). 
Following entry into the host cell via these proteins, several steps must occur in order for 
viral infection to continue. 
 
Viral Infection and Immune Response 
The viral infection process is quite unique compared to other infectious 
pathogens. Viruses are unable to replicate on their own, so they must hijack host cell 
machinery in order to replicate. The virus first attaches to the surface of the host cell 
using its G protein, and it enters the cell via endocytosis. Endocytosis involves the cell 
membrane surrounding the entire viral particle and pushing it into the cell. Enveloped 
viruses are able to fuse directly with the host cell membrane using the F protein. Once 
inside the cell, the viral capsid is degraded by host cell proteins leaving the genome 
naked. The genome is now available to be replicated and transcribed (34). The “central 
dogma of molecular biology” describes how any type of genome is actually expressed. It 
tells that the beginning of the process is DNA, which is transcribed into RNA, which is 
then translated into proteins. However, RNA can go either direction: back into DNA via 
reverse transcription or into proteins via translation (35). If the genome is ssRNA, there  
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Figure 2: Anatomy of a viral particle: The figure depicts the viral genome in green, the 
capsid in red, the envelope in blue, and the surface F and G proteins in orange and yellow. 
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are two different ways the cell can go about replicating it. If the ssRNA is in the 
orientation in which it can directly be translated, it is called a positive-sense ssRNA, or 
+ssRNA. In this case, the RNA can be translated directly into viral proteins. If the ssRNA 
is in the opposite orientation, it is called negative-sense ssRNA or -ssRNA. In this case, 
the virus must utilize an enzyme called reverse transcriptase to allow the genome to 
create DNA from the ssRNA, then transcribe that DNA into a piece of ssRNA that can be 
translated. All translation takes place via host cell mechanisms and materials (36). 
The next step in the viral infection process involves assembly of all the translated 
materials into functional virions. Hundreds of virions can be created in one host cell. The 
last step is egress, or release of new virions into the environment to give them the 
opportunity to infect more healthy cells. There are a few different ways that this can 
happen. For animal viruses, this process can happen via a process called budding, which 
involves the viral particles exiting the cell through bubbles of the membrane without 
actually killing the cell. They can also leave the cell by actually destroying the host cell. 
This happens when the cell acquires hundreds of viral particles until it can hold no more, 
then there is a signal triggering lysis or programmed cell death, which releases all the 
virions together (34) (Figure 3). Although this is quite a sophisticated process, the cell 
can defend itself from the pathogen using the immune system. 
There are two different types of immune system response to pathogens: the innate 
and the adaptive. The first time a cell is exposed to a particular type of virus, it has no 
“knowledge” of ever seeing that virus before. This is the innate immune response; the 
cell’s mechanisms are not specialized to deal with this type of virus, so they use  
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Figure 3: Life cycle of animal viruses 
Adapted from https://courses.lumenlearning.com/microbiology/chapter/the-viral-life-cycle/ 
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mechanisms that are broader and can interact with any type of pathogen. The adaptive 
immune response is what happens when the pathogen has been in contact with the cell 
before, and the cell has developed mechanisms that are specific to fight off this pathogen 
in particular. The adaptive immune response is more efficient than the innate. There are 
several steps that must happen in order for the innate immune response to be carried out. 
The first, of course, is for the cell to come in contact with the pathogen, in this case this is 
a virus. The innate immune system must recognize that the viral particle is foreign, that 
is, it is “non-self.” Proteins called pattern recognition receptors, either on the cell surface 
or inside the cellular cytoplasm, are responsible for this distinction. These will usually 
detect double-stranded RNA (dsRNA) or single-stranded RNA (ssRNA), which are 
usually not seen in healthy cells. The cytoplasmic pattern recognition receptor RIG-1 
binds viral RNAs, which triggers the release of several different parts of the innate 
immune system. Firstly, cytokines will be synthesized, which are the main production of 
the innate system. Another class of pattern recognition receptors are called toll-like 
receptors (TLRs), which sense the surface glycoproteins as well as dsRNA and ssRNA. 
TLR activation also leads to the synthesis of cytokines (33). 
Cytokines are simply any number of substances secreted by the immune system 
that have an effect on other cells. There are more than 80 known cytokines that are 
secreted by the innate immune cells. One class of cytokines is known as interferons or 
IFNs. The first cytokines that are created are IFNs α and β. They are able to act locally by 
binding to receptors on neighboring cells, which can preemptively produce antiviral 
components in preparation for viral exposure. Other cytokine classes include tumor 
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necrosis factors (TNFs), and interleukins (ILs). Various classes of cytokines are also 
responsible for the symptoms of a viral sickness, including fever, fatigue, and nausea. 
Cytokine incidence is one of the earliest indications of viral infection (33). 
Along with cytokines, sentinel cells, which include dendritic cells and 
macrophages, are also an important part of the innate immune response. These cells are 
the security system of the cell, and they search for signs of infection in the body. 
Dendritic cells interact with cytokines and absorb viral proteins released from dead 
infected cells. They will then produce more cytokines to amplify the cellular response. 
Usually, this amplification of cytokines is enough to eliminate whatever pathogen is 
taking over, however if the system is overwhelmed and viral replication continues 
regardless, then the second line of defense is put into action, which includes development 
of the adaptive immune response (33). However, patients who have a weak immune 
system, or pathogens that are particularly strong will deplete the human body before it can 
even deploy the second line of defense. To combat this, people will proactively create a 
second line of defense for particular pathogens and particular people in the form of 
vaccines. 
On average, the human body may take up to a week to form pieces of the adaptive 
immune system that can more efficiently fight off a specific virus. Meanwhile, the body 
continues to get sicker and symptoms of infection continue to increase in severity and 
could even result in mortality. To prevent this tragedy from occurring, vaccines can be 
administered before people have a chance to come in contact with these pathogens. A 
vaccine is an attenuated form of the pathogen that is trying to be protected against. The 
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pathogen is weakened so it is very easy for the pathogen to be killed off by the innate 
immune system and is therefore very easy for the adaptive immune system to create 
mechanisms that will quickly kill off the pathogen if it comes in contact with the person 
again. This is often the most common strategy for combatting viral infections-preventing 
them from occurring in the first place by beefing up the immune system to be able to deal 
with them (37). Vaccines can be tricky for certain populations, however. If a person has a 
certain disease that depletes his or her immune system, they may not be able to fight off 
even the attenuated version of the pathogen without getting very sick. This can also be an 
issue in infants; when babies are first born, they have very weak and undeveloped 
immune systems that are not able to fight off pathogens with ease. Often, children will 
have to receive some of their vaccines when they are a bit older and their immune 
systems can handle the attenuated pathogen. Several pathogens are harmless to adults, 
and even children of certain ages, but are detrimental to the weak immune systems of 
babies. One such pathogen is Respiratory Syncytial Virus, or RSV. 
 
Intro to RSV 
 RSV is a human upper and lower respiratory pathogen mainly impacting infants 0-
12 months and the elderly, and it remains a leading cause of mortality for these 
populations worldwide (1-3). RSV is an enveloped, -ssRNA virus in the Pneumoviridae 
family. The RSV genome is about 16kb long, encoding for 10 genes that can be translated 
into 11 proteins (4). To propagate infection, the G and F proteins interact with host 
surface proteins to allow entry into the cell. RSV F undergoes a conformational change 
DeFord 15 
 
triggered by attachment from a pre-fusion to a post-fusion state (4). Being the first piece 
of the virus that the immune system is exposed to, RSV F and G proteins continue to be 
the leading trigger of production of neutralizing antibodies, as well as other immune 
responses after exposure to RSV (4-7). Explication of viral F and G have led to several 
studies looking to design F and G component vaccines for RSV (8-11). These vaccines 
have been shown to elicit antibody production in the elderly, however there is a history of 
enhanced disease after utilization of these vaccines in infants, the largest target population 
for the virus (12-14). Due to this setback, studies are now focusing only on live-
attenuated RSV for vaccine preparation in infants (15-16).  
 While infection in adults causes only a mild cold, RSV infection in infants causes 
severe respiratory disease with symptoms such as fever, wheezing, difficulty breathing, 
and blue skin color due to lack of oxygen. These symptoms usually appear four to six 
days after exposure to the pathogen. Some infants can be affected even more severely, 
causing need for extensive hospital stay and even fatality. RSV infection can also cause 
permanent long-term effects as children get older, including asthma, chronic 
inflammation of lungs and airways, and repeated infection. The illness can be spread via 
airborne pathogen or direct contact from infected individuals, or individuals who are 
carrying the virus. The virus can also live on surfaces for several hours, so some 
individuals can be infected by coming in contact with a surface containing the pathogen. 
This is the most common way the pathogen can spread around daycares; it can be present 
on a countertop or a toy and spread to children, then children can take it home and spread 
it to their siblings who may be more susceptible to the pathogen (40). 
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 Nearly 33 million cases of RSV infection are reported in children annually, with 
3.4 million of these cases resulting in hospitalization. Obviously, high-risk populations 
(premature infants, immune deficient children, etc) are more at risk for hospitalization 
and death, and they are often the focus of research, although 70+% of hospitalizations 
occur in children with no underlying conditions. Hospitalization rates increase with 
decreased age, with the highest incidence being in the first three months of life. Infection 
rates peak in winter months in the Western world, which peak in December. RSV is 
particularly dangerous because there is a high risk of co-infections with other seasonal 
respiratory illnesses, such as influenza, rhinovirus, and human metapneumovirus, as well 
as various bacteria. These co-infections are commonly more dangerous than initial 
infection of the virus. The mortality rate of RSV continues to be crippling to society. In 
2010, RSV was estimated to have accounted for 1.6% of all deaths globally. The current 
data regarding RSV mortality rate in the West is less than 5%, but higher rates are seen in 
low-income countries with less supplies. Although advances in medicine have been 
made, the mortality rate for RSV has remained fairly stable since the 1970s (39). This is 
perhaps due to the notorious instability and complexity of RSV presents unique 
challenges in developing a live-attenuated vaccine for the virus (4-6, 16). 
 
RSV Project 
 RSV infection has been shown to be seasonal in temperate climates, and previous 
studies have suggested that weather conditions such as temperature may play a role in 
development of RSV infection (17). The thermal stability of the virus in question is vital 
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for vaccine design. When designing a new vaccine, it is known that it will be stored in 
refrigeration temperature (4oC) in order to transport it to different parts of the world to be 
administered. Also, the vaccine will have to be administered into the body, at body 
temperature (37oC). If the vaccine is unstable to temperature and it is inactivated at 
refrigeration or body temperature, it will not be effective at recruiting the innate immune 
system, then creating specific antibodies to later use the adaptive immune system. 
Basically, a vaccine unstable to temperature will not be effective (4-6; 16).  
Not even 10 years after RSV’s first documentation in humans, several studies 
reported the intrinsic instability of RSV to cold temperatures, specifically for storage (18-
19). The first investigation of physical stability of RSV was published in 1964 using the 
Long laboratory strain, which illustrated that the virus showed significant sensitivity to 
incubation at 37℃ and 25℃, showing 10-fold reductions in viral titer by 24h and 48h 
post-infection (18). This study demonstrated the general conditions of optimal stability of 
the virus however it was limited to the study of only one laboratory strain of RSV. A 
study in 2016 examined the thermal stability of two different laboratory strains differing 
by only the F protein, A2 and A2-line19F, showing incubation of each strain at 4℃ and 
37℃. This study found that the A2 strain incubated at 4℃ and 37℃ exhibited a 
significantly higher reduction in titer after 7d of incubation compared to the A2-line19F 
strain in the same incubation conditions (20) (Figure 4). These results suggest that the F 
protein contributes to the thermal stability of RSV. Ultimately, these previous studies 
outline the intrinsic thermal instability of RSV and suggest that RSV strain-specific  
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Figure 4: Difference of thermal stability between two strains of RSV with different 
F proteins: Thermal inactivation assays of RSV strains A2 and A2-line19F at 4°C and 
37°C. Viruses were incubated for 7 days at the designated temperature before titering. 
Reductions in titer are reported as a percent of day 0.  
 
 
Adapted from Stobart and Rostad et al. 2016. Nat. Commun. 7:13916. 
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differences may lead to significant differences in environmental stability. These strain-
specific differences are likely within the F protein of RSV. 
 To explore this hypothesis, we used a panel of recombinant RSV strains, all 
containing a backbone of the A2 laboratory strain, and differing only by the F and/or G 
genes (Figure 1). These strains were examined to identify strain-specific differences in 
growth kinetics and viral stability to thermal extremes. This study shows the first stability 
data for circulating clinical RSV strains compared to laboratory strains. Understanding 
differences between strains, specifically those circulating, may provide strategies to 
stabilize a live-attenuated vaccine preparation for RSV. 
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Materials and Methods 
 
Cells and Virus Stock:  
 HEp2 cells and Vero cells were cultured and stored in Minimal Essential Medium 
(MEM) containing 10% Fetal Bovine Serum (FBS) and 1µg/mL penicillin + streptomycin 
+ amphotericin B mixture. The viruses used in this study express mKate2 red fluorescent 
protein and were recovered using a reverse genetics method using A2 background. Each 
strain differs only in expression of the F and/or G proteins. RSV strains A2-mKate2, A2-
mKate2-line19F, A2-mKate2-(A/1998/12-21)GF [A2-12-21GF], A2-mKate2-(Riyadh 
A/91/2009)GF [A2-91/09GF], and A2-mKate2-(TX-11-56GF) [A2-TX11-56GF] were 
used in this study. All recombinant strains were provided by Martin Moore (Emory 
University). Virus stocks were propagated from HEp2 cells, flash frozen in a dry ice and 
isopropanol bath and stored at -80ᵒC until needed. 
 
Viral Replication in Cell Lines 
 Six-well plates containing HEp2 or Vero cells at 70%-90% confluency were 
infected with a 0.01 Multiplicity of Infection (MOI) and rocked for 45 minutes at room 
temperature. After infection, the virus suspension was removed from the cells, and the 
cells were washed twice with 2mL Phosphate Buffered Saline (PBS). The cells were then 
incubated in 2mL MEM at 37ᵒC and 5% CO2 during the time course. At 0, 1, 2, 3, and 4 
days post-infection, cells were scraped into the media, vortexed, flash frozen in dry ice 
and isopropanol, and stored at -80ᵒC until titering. Images were obtained at each time 
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point using [computer program]. Viral titers were collected using a Fluorescent Focus 
Units (FFU) quantification assay 24 hours after infection on HEp2 cells. 
 
Thermal Stability Assays: 
 Several prepared vials of each strain of virus were combined in a 15mL conical 
with PBS at a 1:2 ratio. Three suspensions were prepared for each strain for storage at 
4ᵒC, 32ᵒC, and 37ᵒC. After suspension and after 1, 3, and 7 days, 1mL samples of the 
virus were collected and flash frozen in dry ice and isopropanol and stored at -80ᵒC until 
titering. Titers were collected using the FFU method as mentioned above. Freeze-thaw 
stability was determined by combining several aliquots of each strain of virus in a 15mL 
conical and subjecting each conical to 5 cycles of flash freezing in dry ice and 
isopropanol and thawing completely. After 0, 1, 3, and 5 cycles, 1mL samples were 
collected and transferred to 96-well dilution plates for FFU titering. 
 
Syncytia Measurement 
 At least 62 syncytia were measured for each viral strain. Syncytia were measured 
using ImageJ program.  
 
Statistics 
 To test for differences in growth rates between RSV strains in different cell lines, 
we fit logistic growth models. All growth curve data were log transformed, and a 3-
parameter logistic growth model was fir to each cell type by least squares (25-26). 
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Parameter estimates and 95% confidence intervals were generated for each strain. The 
parameters were: 1:k maximum slope (maximum growth rate), 2: inflection point (time to 
maximum growth), and 3: asymptote (maximum titer). Models were fit using JMP (SAS 
Institute, Cary NC, USA). 
 To test for differences in decay rates between strains due to temperature and 
freeze-thaw cycles, an exponential decay model was fit using least squares. For each 
experiment, percent titer remaining was calculated by normalizing to initial titer. Decay 
rates were compared by conducting an analysis of covariance (ANCOVA) on ln-
transformed data. For each ANCOVA, viral strain was the categorical covariate and the 
continuous predictor was time or number of freeze-thaw cycles. All data were diagnosed 
to meet the normality and equal variance assumptions of ANCOVA. The decay rate 
(slope of the regression, k) was estimated by least squares for each strain. When there was 
a significant interaction between the slope (decay rate) and strain, this indicated a 
difference in decay rates between strains, and pairwise comparisons were conducted 
between strain specific decay rates. For ease of interpretation the decay rate parameter 
estimate is presented as a half-life (lambda = ln (2) k-1), and statistical significance was 
determined at the p<0.05 level. All ANCOVAs were conducted using the fit model 
procedure in JMP (SAS institute, Cary, NC, USA). 
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Results 
 
Replication Kinetics of RSV Panel: 
 A panel of RSV strains generated using an A2 reverse genetics system, which 
express a red fluorescent reporter gene, monomeric Katushka 2 (mKate2), and that differ 
only in expression of F only (A2-line19F) or F and G proteins (A2-91/09GF, A2-12-
21GF, and A2-TX-11-56GF) were developed in order to evaluate antibody neutralization 
activation susceptibility (Figure 5B) (20, 23). To examine replication kinetics of these 
strains, HEp-2 and Vero cells were infected with the panel at 0.01 MOI (Figure 6A and 
B). The replication kinetics were consistent between cell types however, significant 
differences were observed between several strains in each cell type. A2 infection 
correlated with complete dissociation of Hep2 and Vero monolayers before the other 
strains exhibited maximum replication kinetics titers in both cell types (Figure 6B). Strain 
A2 also exhibited greater replication kinetics than A2-line19F in Hep2 and Vero cells, 
which is consistent with previous data (24). Strains A2-91/09GF and A2-12-21GF had 
similar replication kinetics compared to A2, but greater than A2-line19F and TX11-56. In 
both cell types, TX11-56 exhibited delayed replication kinetics and the lowest maximal 
replication rate of all the panel strains (Figure 6A and D; Table 1).  
 To evaluate the role of the surface glycoproteins F and G on virus-mediated 
fusion, syncytia size was determined for each of the viruses in HEp-2 cells after 2 days of 
infection. All 5 strains were able to form syncytia, but significantly different sizes were 
observed between strains. Strains A2 and A2-line19F exhibited the largest syncytia and  
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Figure 5: Schematic of RSV genome and panel of recombinant strains used in this 
study. (A) RSV genome, which expresses Katushka 2 (mKate2), a red fluorescent 
reporter, and the F gene only (A2-line19F) or F and G genes only of laboratory or clinical 
strains (B), were recovered using an A2-based reverse genetics system (21-22). 
RSV Strain Background F Gene Source G Gene Source 
A2 [A] RSV A2-K A2 A2 
A2-line19F [A] RSV A2-K Line19 A2 
A2-12-21GF [A] RSV A2-K A/1998/12-21 A/1988/12-21 
A2-91/09GF [A] RSV A2-K Riyadh A/91/2009 Riyadh A/91/2009 
A2-TX11-56GF [B] RSV A2-K TX11-56 TX11-56 
A 
 
 
 
B 
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Figure 6: RSV replication kinetics and infectivity of a panel of recombinant RSV 
strains differing in G and/or F expression in HEp2 and Vero cells. Replication viral 
titers were collected by counting FFUs after infection with an MOI of 0.01 in either HEp-
2 (A) or Vero (D) cells. Markers (black for A2, dashed for A2-line19F, orange for 12-21, 
green for 91/09, and red for TX11-56) indicate the mean titers at each time point and 
error bars represent ± SEM of 2+ experimental replicates. (B) Representative images 
were taken over 4 days before collection for titering. Disconnection of the monolayer for 
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each strain is denoted by the blue dotted line. (C) Quantification of syncytia size was 
performed on infected HEp-2 cells after 48 h of infection. At least 62 syncytia over 4 
experimental replicates were measured. The mean size of syncytia for each virus strain is 
denoted by a black bar. (E) Using the replication data for HEp2 and Vero infections, the 
maximal slopes were calculated with error bars denoting the SEM for each virus. Letters 
and symbols above each virus and cell condition denote statistical grouping within the 
cell type; viruses within cell lines that share a letter or symbol do not differ significantly 
(p > 0.05).  
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Figure 7: Thermal stability of RSV panel. Virus strains were incubated at 4℃, 32℃, or 
37℃ for 0, 1, 3, and 7 days post-incubation before titering using FFU on HEp2 cells. 
Percent reductions in titer are reported for each time point relative to day 0 time point 
before incubation, which is set at 100% (1). Error bars indicate the mean titers at each 
time point ± SEM of 3 replicates. Letters and symbols above each virus and cell condition 
denote statistical grouping within cell type. Viruses sharing the same letter or symbol for 
a given cell type are not significantly different (p>0.05).  
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Figure 8: Stability of RSV Panel after Cycles of Freezing and Thawing: Viruses were 
flash-frozen in a dry ice-isopropanol bath and thawed over 0, 1, 3, and 5 cycles, with FFU 
titers collected following each interval on HEp2 cells. Titer reductions are reported as a 
percent of the initial titer, the 0 cycles point, which is set at 100%. Error bars represent 
mean percentage reductions in titer compared to no treatment ± SEM of 3 replicates. No 
statistically significant differences were observed. 
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Table 1 A2 A2-
line19F 
A2-12-
21GF 
A2-
91/09GF 
A2-TX11-
56GF 
Average 
Maximal 
Replication 
Kinetics  
(log10 
FFU/day) 
HEp
2  
 
 
Vero  
4.2 
log10FFU/
d 
CI (2.5, 
5.9) 
 
3.4 
log10FFU 
CI (2.7, 
4.2) 
1.3 
log10FFU/
d 
CI (1.1, 
1.5) 
 
1.6 
log10FFU/
d 
CI (1.3, 
1.9) 
2.3 
log10FFU/
d 
CI (1.9, 
2.7) 
 
2.4 
log10FFU/
d 
CI (1.9, 
2.8) 
2.5 
log10FFU/
d 
CI (2.1, 
2.9) 
 
2.8 
log10FFU/
d 
CI (2.3, 
3.3) 
1.0 
log10FFU/
d 
CI (0.8, 
1.2) 
 
1.2 
log10FFU/
d 
CI (0.9, 
1.5) 
2.3 
log10FFU/
d 
 
 
2.3 
log10FFU/
d 
Thermal 
Inactivation 
Half-life (in 
hours) at 
Temperatures
: 
4°C 
 
 
32°C 
 
 
37°C 
 
12.9 h 
CI (10.0, 
18.3) 
 
7.2 h 
CI (6.2, 
8.5) 
 
7.0 h 
CI (5.4, 
9.8) 
104.9 h 
CI (60.6, 
390.1) 
 
11.3 h 
CI (8.5, 
17.1) 
 
6.4 h 
CI (5.8, 
7.1) 
19.6 h 
CI (16.2, 
24.8) 
 
7.2 h 
CI (6.2, 
8.6) 
 
6.6 h 
CI (5.6, 
8.0) 
8.6 h 
CI (6.8, 
11.4) 
 
7.4 h 
CI (5.6, 
11.0) 
 
6.4 h 
CI (5.1, 
8.6) 
11.9 h 
CI (9.0, 
17.6) 
 
7.3 h 
CI (6.0, 
9.5) 
 
6.7 h 
CI (5.3, 
8.9) 
31.6 h (1.3 
d) 
 
 
8.1 h 
 
 
6.6 h 
Freeze-thaw Cycles to 
50% Reduction in 
Titers 
1.2 cycles 
 
1.7 cycles 
 
1.4 cycles 1.5 cycles 1.2 cycles 1.5 cycles 
 
Table 1: Summary of the Physical and Functional Characteristics of a Panel of 
Recombinant RSV Viruses Differing in G and/or F Protein Expression. The average 
values for each of the viruses and the average for the entire panel are provided for each 
condition tested. Where applicable, the 95% confidence interval (CI) is provided. 
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formed syncytia that were significantly larger than 91/09 and TX11-56. Strain 12-21 
displayed significantly lower syncytia sizes than all other strains (Figure 6C and E).  
 
Thermal Stability 
 To evaluate strain specific F and G differences in thermal stability, aliquots of 
each strain were incubated at 4℃ (refrigeration temp), 32℃ (upper airway temp), and 
37℃ (lower airway temp/core body temperature) over 7 days. For all strains, higher 
temperature resulted in higher incidence of inactivation. At 4℃ and 32℃, titers were 
detected after 7 days incubation, but at 37℃, no titer was detected after 7 days incubation 
for all strains. The greatest difference between strains was observed at incubation at 4℃ 
and 32℃. A2-line19F exhibited higher stability at these temperatures than the other 
strains in the panel, with titer reductions of 54.9% and 82.3% for the 4℃ scenario, and 
53.1% and 73.9% at the 32℃ scenario. All other strains at these two temperatures 
retained less than 1% of the original titer after 7 days of incubation at either temperature. 
Laboratory strain A2 exhibited lower stability than other strains at 4℃, and there were no 
significant differences in thermal stability among each strain at 37℃ incubation (Figure 
7; Table 1). 
 Freeze-thaw stability was used to evaluate the impact of reuse of virus stocks in 
research, as well as measure stability of virus structure between strains. To determine the 
role of the F and G proteins on stability following freeze-thaw cycles, the panel of RSV 
strains was subjected to 5 cycles of flash freezing and thawing (Figure 8; Table 1). No 
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significant differences were observed among the strains, although subtle differences can 
be seen. 
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Discussion 
 Progress on a live attenuated RSV vaccine for infants is a high priority of 
numerous national and international public health organizations, including the World 
Health Organization (WHO) (27). However, the environmental instability associated with 
RSV remains a huge obstacle. Although several clinical isolates have been recently 
obtained, little is known regarding structural and functional differences between strains. 
This study examines the role of varied F and G proteins of RSV on virus growth and 
stability. 
 Significant differences in thermal stability and replication were observed between 
strains. Laboratory strain A2, a common strain used for vaccine preparation attempts, 
demonstrated the highest replication kinetics among the panel, including higher 
replication than A2-line19F, which was observed in a previous study (28). Strain A2-
TX11-56GF, which expresses a B type F and G gene, demonstrated reduced replication 
kinetics in HEp2 and Vero cells. As shown in results of F and G during viral infection, 
RSV strains have been known to differ in infectivity and replication, although the 
differences in infectivity also suggest that there are likely dynamic differences in structure 
and function associated with one or both of these proteins.  
Examining the role of these proteins on thermal stability, we found that increasing 
temperatures were associated with higher inactivation of the virus. Additionally, thermal 
stability differences between strains were more apparent at lower temperatures, with no 
significant difference observed at 37℃. Previous studies report a 104-105-fold reduction 
in A2 titer compared to less than 10-fold reduction for A2-line19F over 7 days at 4℃ (20, 
DeFord 33 
 
22). We observed similar results between A2 and A2-line19F. These data further support 
that RSV F, RSV G, or a combination of the two are likely to serve as the primary factors 
of thermal stability of the virus. 
 For each strain of RSV observed, the virus was more stable at cold temperature 
than warm temperature. This suggests that perhaps people in colder climates are more 
susceptible to the virus than people living in warmer clients. It is possible that the virus 
can just survive better in colder conditions than warmer conditions. RSV may be more 
dangerous in nature in colder climates and during colder seasons but could be more 
dangerous in indoor conditions at warmer climates or in warmer seasons. As air 
conditioning is kicked up during the summer, especially in daycare and hospital settings, 
the colder air inside may promote higher incidences of the pathogen living on surfaces, 
and for a longer period of time. It may help, also, for patients recovering from RSV to be 
held in a warm room so the virus has a lower chance of survival. To confirm this theory, 
it would help to conduct a study in the future of RSV infections in colder vs warmer 
climates, as well as at colder vs warmer seasons of the year to see if there is significant 
difference between incidences of infection and mortality between the two climates. 
Several viruses included flu and common cold viruses are known to have a “season,” and 
it may be the same for RSV for this reason in particular. 
 Interestingly, we observed that replication kinetics and thermal stability are 
independent of one another and may actually represent a fitness trade-off for the virus. 
A2-line19F showed reduced replication compared to A2 in HEp2 and Vero cells, yet was 
significantly more stable to temperature at 4℃ and 32℃. Future studies should indicate 
DeFord 34 
 
how stability and function of RSV F are correlated during RSV infection. It still remains 
unclear what role RSV G plays in growth and stability, as most panel strains were cloned 
with F and G together. A previous study found evidence to support the hypothesis that F 
and G likely contain co-evolved interactions, which facilitate higher efficiency for 
attachment and entry (29). It may not be surprising, then, assume a potential role of RSV 
G in the stabilization of RSV strains. 
 Replication kinetics and thermal stability were also unrelated to syncytia size 
produced by different strains of the virus. A2 and A2-line19F exhibited the largest 
syncytia; the former was the quickest growing under regular conditions and the latter was 
the most stable to temperature. It seemed out of place to see similarity between syncytia 
size between these two strains, but larger differences between growth kinetics. Perhaps 
strain A2-line19F has a delayed trigger of lysis or apoptosis (programmed cell death) of 
the infected cell compared to A2. This would explain the large spike in growth and early 
monolayer destruction of A2 and later destruction of monolayer in A2-line19F. In this 
case, they could have the same sizes of syncytia but differing growth kinetics.  
Strains 91/09 and TX11-56 were the next largest syncytia seen. Strain TX11-56 
was the weakest strain in terms of growth kinetics and thermal stability, while strain 
91/09 was about in the middle for both scenarios. This difference could be due to the 
amount of syncytia that can form at a time for each strain. It may be a bit more 
complicated for strain TX11-56 though; the qualitative figure showing growth kinetics 
showed weak patches of infection for this strain. Perhaps TX11-56 has quicker lytic 
triggers than 91/09, but creates syncytia much further apart. In other words, TX11-56 
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produces syncytia and triggers lysis very quickly, but only creates a few syncytia at a time 
due to its weaker nature. Then, strain 91/09 probably creates syncytia quickly and has 
lytic triggers quickly but can form more syncytia at a time which is why it shows quicker 
growth under normal conditions and shows more infection at a time than TX11-56 does 
in the qualitative figure. Strain 12-21 showed significantly lower syncytia sizes than all 
the others but was intermediate in terms of growth kinetics and thermal stability. This 
may be due to unusually quick lytic trigger of this strain of RSV. Several syncytia can 
form at the same time rapidly, but the lytic trigger cuts the lifespan of each syncytia short, 
so it has less time to grow. 
One important issue with this study in particular is that it was done on non-
respiratory cancer cells, while actual infection takes place on human respiratory cells. 
This study obviously does not show true infection patterns of different strains of RSV. 
The study would be more credible if it were done on actual human respiratory cells, and 
in the future a study of this sort would help to truly confirm the results of the study. This 
study may be very difficult however, due to the complex nature of growing and 
maintaining human respiratory cells in a laboratory setting (38). Also, in the future, these 
same studies should be done in mice or another model organism to see if physiological 
data show the same distinctions and differences that are seen on this in vitro examination.  
 In conclusion, we demonstrate a detailed analysis of strain specific differences in 
RSV laboratory and clinical strains differing only by F and/or G proteins on replication 
potential and thermal stability. We found that A2-line19F exhibits enhanced thermal 
stability, which may provide a difference target for vaccine development than commonly 
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used A2 strain. While this study is limited to a small subset of F and G genes, we 
demonstrate that significant phenotypic differences exist among RSV strains, and warrant 
future study of laboratory and circulating strains to better understand ways of eliminating 
spread of RSV in high risk populations, as well as contribute to future design of effective 
live-attenuated vaccine candidates. 
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